<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; OECD</title>
	<atom:link href="http://www.tapanray.in/tag/oecd/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Indian Pharma: Optimism, Concern and Retaining Trust</title>
		<link>http://www.tapanray.in/indian-pharma-optimism-concern-and-retaining-trust/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharma-optimism-concern-and-retaining-trust</link>
		<comments>http://www.tapanray.in/indian-pharma-optimism-concern-and-retaining-trust/#comments</comments>
		<pubDate>Sun, 08 Oct 2017 23:46:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[concern]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[hard]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[NCAER]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Optimism]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Retaining]]></category>
		<category><![CDATA[skills]]></category>
		<category><![CDATA[soft]]></category>
		<category><![CDATA[Survey]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[trust]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8457</guid>
		<description><![CDATA[As many would know, the significance of trust is profound. It is virtually all-pervasive. Building trust is fundamental in retaining any relationship – be it in the family, society or even in business, such as pharmaceuticals. For long-term success and &#8230; <a href="http://www.tapanray.in/indian-pharma-optimism-concern-and-retaining-trust/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharma-optimism-concern-and-retaining-trust/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control And National Health Security</title>
		<link>http://www.tapanray.in/drug-price-control-and-national-health-security/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-and-national-health-security</link>
		<comments>http://www.tapanray.in/drug-price-control-and-national-health-security/#comments</comments>
		<pubDate>Mon, 25 Sep 2017 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[funded]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[irrelevant]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[mentality]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulation]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[silo]]></category>
		<category><![CDATA[State]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8431</guid>
		<description><![CDATA[&#8216;Without Providing Affordable Medicines, There Can&#8217;t be Health Security&#8217;, said the Union Minister of Chemicals and Fertilizers of India, as reported on September 22, 2017. Although, the Minister made this remark while discussing Government price control on cardiac stents in &#8230; <a href="http://www.tapanray.in/drug-price-control-and-national-health-security/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-and-national-health-security/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Counterfeit Drugs In India: A Malady Much Deeper</title>
		<link>http://www.tapanray.in/counterfeit-drugs-in-india-a-malady-much-deeper/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=counterfeit-drugs-in-india-a-malady-much-deeper</link>
		<comments>http://www.tapanray.in/counterfeit-drugs-in-india-a-malady-much-deeper/#comments</comments>
		<pubDate>Sun, 23 Oct 2016 23:39:00 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[anti-counterfeit]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[deeper]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intent]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[malady]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[types]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7907</guid>
		<description><![CDATA[Many debates and discussions continue being lined up in India almost regularly, generally by the pharma trade associations, besides a few others, on the issue of counterfeit drugs. A good number of these events are sponsored by the global and &#8230; <a href="http://www.tapanray.in/counterfeit-drugs-in-india-a-malady-much-deeper/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/counterfeit-drugs-in-india-a-malady-much-deeper/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Health Care: &#8220;India Has Moved From Strength To Strength!”</title>
		<link>http://www.tapanray.in/health-care-india-has-moved-from-strength-to-strength/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=health-care-india-has-moved-from-strength-to-strength</link>
		<comments>http://www.tapanray.in/health-care-india-has-moved-from-strength-to-strength/#comments</comments>
		<pubDate>Mon, 02 Nov 2015 00:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bangladesh]]></category>
		<category><![CDATA[Bhutan]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[child]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[Editor-in- Chief]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[gandhi]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Horton]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indicators]]></category>
		<category><![CDATA[Maldives]]></category>
		<category><![CDATA[Malnutrition]]></category>
		<category><![CDATA[Maneka]]></category>
		<category><![CDATA[meal]]></category>
		<category><![CDATA[mid-day]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[moved]]></category>
		<category><![CDATA[Nepal]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Richard]]></category>
		<category><![CDATA[Sri Lanka]]></category>
		<category><![CDATA[strength]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[The Lancet]]></category>
		<category><![CDATA[Vietnam]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7227</guid>
		<description><![CDATA[The above flabbergasting assertion came recently from the Union Government of India in context of current health care system in the country.  To be specific, this proclamation of the Ministry of Health was reportedly made at its ‘point by point &#8230; <a href="http://www.tapanray.in/health-care-india-has-moved-from-strength-to-strength/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/health-care-india-has-moved-from-strength-to-strength/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Just 16% Of Indian Population Has Access To Free Or Partially-Free Health Care?</title>
		<link>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=just-16-of-indian-population-has-access-to-free-or-partially-free-health-care</link>
		<comments>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/#comments</comments>
		<pubDate>Mon, 05 Oct 2015 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[16]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[2015-14]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[BRICS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[chronic]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[debates]]></category>
		<category><![CDATA[Dengue]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[job]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[partially]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[population]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Rangarajan]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRP]]></category>
		<category><![CDATA[TV]]></category>
		<category><![CDATA[up-market]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7121</guid>
		<description><![CDATA[Is health care currently a low priority area for the Government of India? Probably yes, and thus it is worth trying to fathom it out. Besides planned frugal spending on overall public health in 2015-16, even as compared to the past &#8230; <a href="http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/just-16-of-indian-population-has-access-to-free-or-partially-free-health-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>India: Tops The GDP Growth, Remains At The Bottom On Health Care</title>
		<link>http://www.tapanray.in/india-tops-the-gdp-growth-remains-at-the-bottom-on-health-care/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-tops-the-gdp-growth-remains-at-the-bottom-on-health-care</link>
		<comments>http://www.tapanray.in/india-tops-the-gdp-growth-remains-at-the-bottom-on-health-care/#comments</comments>
		<pubDate>Mon, 13 Jul 2015 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2014]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[at the bottom in healthcare]]></category>
		<category><![CDATA[bottom]]></category>
		<category><![CDATA[BRICS]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[GDP]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6802</guid>
		<description><![CDATA[On February 9, 2015, the Wall Street Journal (WSJ) reported, “India’s statistics ministry surprised economists when it unveiled the new numbers for the growth of India’s gross domestic product. It ratcheted up India’s GDP growth figures using a new methodology that &#8230; <a href="http://www.tapanray.in/india-tops-the-gdp-growth-remains-at-the-bottom-on-health-care/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-tops-the-gdp-growth-remains-at-the-bottom-on-health-care/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Frugal Public Resource Allocation Quo Vadis Healthcare in India?</title>
		<link>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india</link>
		<comments>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/#comments</comments>
		<pubDate>Mon, 16 Mar 2015 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[14th]]></category>
		<category><![CDATA[2014-15]]></category>
		<category><![CDATA[2015-16]]></category>
		<category><![CDATA[Budget]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[erstwhile]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[frugalNational]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Policy 2015]]></category>
		<category><![CDATA[quo vadis]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6448</guid>
		<description><![CDATA[The memory is still afresh in India. A new political dispensation took charge of the governance of the country, riding on the tidal waves of people’s hope and aspirations, with presumed credibility to ‘Walk the Talk’. The expectations were skyrocketing &#8230; <a href="http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-frugal-public-resource-allocation-quo-vadis-healthcare-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Herceptin Biosimilar Expands Drug Access to Breast Cancer Patients in India</title>
		<link>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india</link>
		<comments>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/#comments</comments>
		<pubDate>Fri, 24 Jan 2014 13:37:35 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[canmab]]></category>
		<category><![CDATA[emcure]]></category>
		<category><![CDATA[expand]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[herclon]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MabThera]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4908</guid>
		<description><![CDATA[Come February 2014, much to the relief of more than 145,000 patients diagnosed with breast cancer in India, Herceptin of Roche, a critical drug for the treatment of the dreaded disease, will face competition, for the first time, from a &#8230; <a href="http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/herceptin-biosimilar-expands-drug-access-to-breast-cancer-patients-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Innovation Absolutely Critical: But NOT Shorn from Ethics, Propriety, Compliance and Values</title>
		<link>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values</link>
		<comments>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/#comments</comments>
		<pubDate>Mon, 20 May 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[bribing]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[buzzword]]></category>
		<category><![CDATA[Caesar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[concealment]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[corrupt]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[denigrating]]></category>
		<category><![CDATA[developed world]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[fines]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[globalized]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grease]]></category>
		<category><![CDATA[guy]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[isolation]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lower]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[overcharging]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[propriety]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[spiritual]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[walk]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wife]]></category>
		<category><![CDATA[X factors]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2481</guid>
		<description><![CDATA[Significant value added innovation is the bedrock of progress of the pharmaceutical industry and is essential for the patients. This is a hard fact. However, this current buzzword – ‘innovation’ can in no way be shorn from soft business necessities &#8230; <a href="http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Patent Conundrum: Ignoring India Will Just Not be Foolhardy, Not An Option Either</title>
		<link>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either</link>
		<comments>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/#comments</comments>
		<pubDate>Mon, 29 Apr 2013 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[direct]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[foolhardy]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Grant]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[infringement]]></category>
		<category><![CDATA[innovator]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[Lamy]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[local]]></category>
		<category><![CDATA[lucrative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nexavar]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[opposition]]></category>
		<category><![CDATA[option]]></category>
		<category><![CDATA[Pascal]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[post]]></category>
		<category><![CDATA[pre]]></category>
		<category><![CDATA[PwC]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[transfer]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[witty]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2267</guid>
		<description><![CDATA[The recent verdict of the Supreme Court against Novartis, upholding the decision of the Indian Patent Office (IPO) against grant of patent to their cancer drug Glivec, based on Section 3(d) of the Indian Patents Act, has caused a flutter &#8230; <a href="http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-conundrum-ignoring-india-will-just-not-be-foolhardy-not-an-option-either/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
